Atox Bio closes $30M round as it speeds through late-stage trials
Israel’s Atox Bio has raised $30 million — the latest in a long line of equity deals — to help push its immune modulators through late-stage clinical trials.
The company is working on immune modulators for patients with severe infections and tissue injury. The company’s lead drug, called Reltecimod, is a peptide that modulates the body’s immune response, boosting the patient’s ability to fight infection while reducing the likelihood of tissue damage to key organs during inflammatory responses to severe infections or injuries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.